Skip to content
    HC

    Hankang Capital

    Shanghai, ChinaFounded 2010
    LinkedIn
    Biotech & Life SciencesHealthcare

    Hankang Capital (formerly Shanghai Jianxin Capital) is a Shanghai-based venture capital firm founded in 2010, focusing on biotech and healthcare investments across China. The firm invests in biomedicine, medical equipment, diagnostic reagents, medical services, and other major health fields, and was renamed from Shanghai Jianxin Capital.

    Deal activity increased 500% year-over-year (6 deals in the last 12 months). Average disclosed round size is $74.0M (across 16 rounds with reported amounts).

    Find people at Hankang Capital on Goldilocks AI

    Portfolio

    14

    Fund Size

    —

    Top Stage

    Series A

    Last 12 Mo

    6

    Team

    JG

    Jian Gong

    VP

    PW

    Pengchong Wang

    VP, Biotech Investments

    RZ

    Rui Zhao

    Senior Associate

    KL

    Kan Lin

    Healthcare Investment

    Y(

    Yuedan (Claire) Chen

    Healthcare investor

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    19 investments
    CompanyRoundAmountDate
    AusperBio logoAusperBioSeries C$120MAug 2026
    VVivacta BiotechnologySeries A$50MApr 2026
    Vivacta logoVivactaSeries A$50MApr 2026
    Pinnacle Medicines logoPinnacle MedicinesSeries B$89MMar 2026
    AusperBio logoAusperBioSeries C$120MJan 2026
    PProviva TherapeuticsSeries A$30MDec 2025
    AusperBio logoAusperBioSeries B$63MSep 2025
    Proviva logoProvivaSeries A$30MJan 2025
    PProviva TherapeuticsSeries A$30MJan 2025
    AusperBio logoAusperBioSeries B$73MDec 2024
    AusperBio logoAusperBioSeries A$37MJul 2024
    Sirius Therapeutics logoSirius TherapeuticsSeries B$50MOct 2023
    SSumgenSeries B—Dec 2021
    Bristar Immunotech logoBristar ImmunotechSeries C—Oct 2021
    Abbisko logoAbbiskoSeries D$123MJan 2021
    和和誉生物Series D$123MJan 2021
    AAbbisko TherapeuticsSeries D$123MJan 2021
    浩博医药 logo浩博医药Series B$73M—
    HHighlightll PharmaSeries C——

    Top Co-Investors

    OrbiMed10 shared
    YuanBio Venture Capital5 shared
    GG14 shared
    CDH Investments4 shared
    Flyer One Ventures3 shared
    Qiming Venture Partners USA3 shared
    LAV3 shared
    Temasek Holdings (Private) Limited3 shared
    Greater Bay Area Homeland Development Fund3 shared
    Lake Bleu Capital3 shared
    Warburg Pincus LLC3 shared
    The Carlyle Group3 shared
    Loyal Valley Capital3 shared
    Viva BioInnovator3 shared
    Decheng Capital2 shared
    Apricot Capital2 shared
    C&D Emerging Industry Equity Investment2 shared
    HongShan2 shared
    Sage2 shared
    Segra Capital Management1 shared

    Last updated: 7 October 2026